Hall Capital Management’s AbbVie ABBV Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $3.29M | Sell |
15,560
-384
| -2% | -$85.2K | 1.18% | 26 |
|
|
2025
Q4 | $3.64M | Sell |
15,944
-115
| -0.7% | -$26.2K | 1.41% | 20 |
|
|
2025
Q3 | $3.72M | Sell |
16,059
-75
| -0.5% | -$15.3K | 1.47% | 19 |
|
|
2025
Q2 | $2.99M | Buy |
16,134
+149
| +0.9% | +$27.7K | 1.27% | 26 |
|
|
2025
Q1 | $3.35M | Hold |
15,985
| – | – | 1.55% | 20 |
|
|
2024
Q4 | $2.84M | Buy |
+15,985
| New | +$2.94M | 1.33% | 24 |
|
|
2024
Q2 | $3.02M | Sell |
17,580
-220
| -1% | -$36.4K | 1.44% | 23 |
|
|
2024
Q1 | $3.24M | Buy |
17,800
+15
| +0.1% | +$2.58K | 1.6% | 21 |
|
|
2023
Q4 | $2.76M | Sell |
17,785
-1,812
| -9% | -$264K | 1.62% | 22 |
|
|
2023
Q3 | $2.92M | Sell |
19,597
-16,969
| -46% | -$2.49M | 1.87% | 19 |
|
|
2023
Q2 | $4.93M | Buy |
36,566
+140
| +0.4% | +$20.5K | 2.78% | 7 |
|
|
2023
Q1 | $5.81M | Sell |
36,426
-859
| -2% | -$131K | 3.44% | 5 |
|
|
2022
Q4 | $6.03M | Buy |
37,285
+177
| +0.5% | +$27.1K | 3.62% | 4 |
|
|
2022
Q3 | $4.98M | Buy |
37,108
+778
| +2% | +$112K | 3.31% | 6 |
|
|
2022
Q2 | $5.56M | Sell |
36,330
-655
| -2% | -$100K | 3.66% | 2 |
|
|
2022
Q1 | $6M | Buy |
36,985
+40
| +0.1% | +$5.81K | 3.51% | 4 |
|
|
2021
Q4 | $5M | Buy |
36,945
+1,085
| +3% | +$128K | 2.83% | 5 |
|
|
2021
Q3 | $3.87M | Buy |
35,860
+388
| +1% | +$44.3K | 2.47% | 12 |
|
|
2021
Q2 | $4M | Buy |
+35,472
| New | +$3.99M | 2.58% | 9 |
|
|
2020
Q4 | $4.08M | Buy |
38,044
+1,855
| +5% | +$178K | 2.95% | 9 |
|
|
2020
Q3 | $3.17M | Buy |
36,189
+952
| +3% | +$89.6K | 2.51% | 11 |
|
|
2020
Q2 | $3.46M | Buy |
35,237
+1,379
| +4% | +$121K | 2.91% | 9 |
|
|
2020
Q1 | $2.58M | Buy |
33,858
+1,890
| +6% | +$161K | 2.64% | 9 |
|
|
2019
Q4 | $2.83M | Buy |
31,968
+28
| +0.1% | +$2.33K | 2.3% | 12 |
|
|
2019
Q3 | $2.42M | Sell |
31,940
-300
| -0.9% | -$20.6K | 2.11% | 15 |
|
|
2019
Q2 | $2.34M | Buy |
32,240
+20
| +0.1% | +$1.57K | 2% | 14 |
|
|
2019
Q1 | $2.6M | Sell |
32,220
-695
| -2% | -$56.9K | 2.26% | 12 |
|
|
2018
Q4 | $3.03M | Sell |
32,915
-910
| -3% | -$80K | 3.02% | 8 |
|
|
2018
Q3 | $3.2M | Buy |
33,825
+150
| +0.4% | +$14.2K | 2.77% | 9 |
|
|
2018
Q2 | $3.12M | Sell |
33,675
-97
| -0.3% | -$9.47K | 2.94% | 8 |
|
|
2018
Q1 | $3.2M | Sell |
33,772
-3,105
| -8% | -$341K | 3.07% | 8 |
|
|
2017
Q4 | $3.57M | Sell |
36,877
-1,270
| -3% | -$120K | 3.12% | 8 |
|
|
2017
Q3 | $3.39M | Sell |
38,147
-91
| -0.2% | -$6.93K | 3.12% | 8 |
|
|
2017
Q2 | $2.77M | Sell |
38,238
-1,381
| -3% | -$92.8K | 2.61% | 9 |
|
|
2017
Q1 | $2.58M | Sell |
39,619
-1,375
| -3% | -$86.4K | 2.45% | 11 |
|
|
2016
Q4 | $2.57M | Buy |
+40,994
| New | +$2.5M | 2.5% | 11 |
|
|
2015
Q3 | $2.42M | Sell |
44,479
-239
| -0.5% | -$15.6K | 2.88% | 7 |
|
|
2015
Q2 | $3M | Sell |
44,718
-1,890
| -4% | -$123K | 3.41% | 5 |
|
|
2015
Q1 | $2.73M | Sell |
46,608
-120
| -0.3% | -$7.25K | 2.83% | 7 |
|
|
2014
Q4 | $3.06M | Buy |
+46,728
| New | +$2.95M | 3.14% | 6 |
|
Other funds holding ABBV
VCM
VPM
Hall Capital Management's ABBV Position: Q1 2026 in Review
Hall Capital Management reduced its AbbVie (ABBV) stake by 2.4% in Q1 2026, selling an estimated $85.2K and leaving 15,560 shares worth $3.29M. The position accounts for 1.18% of the portfolio, ranked #26.
Hall Capital Management first reported a position in ABBV in Q4 2014 and has held it in 40 quarters since. The position peaked at $6.03M in Q4 2022. 4,080 funds tracked by Wall St. Rank hold ABBV as of Q1 2026.
- Hall Capital Management held 15,560 shares of AbbVie worth $3.29M as of Q1 2026.
- Hall Capital Management sold 384 AbbVie shares in Q1 2026, an estimated $85.2K.
- AbbVie made up 1.18% of Hall Capital Management's portfolio in Q1 2026, its #26 holding.
- Hall Capital Management first reported a position in AbbVie in Q4 2014 and has held it in 40 quarters since.
- Hall Capital Management's AbbVie position peaked at $6.03M in Q4 2022.
- 4,080 funds tracked by Wall St. Rank held AbbVie as of Q1 2026.
Based on Hall Capital Management's 13F filing for Q1 2026, filed 11 May 2026.